ERBB2 and non-small cell lung carcinoma: In contrast to the success of EGFR TKIs for EGFR mutant NSCLC, dual EGFR/HER2 (lapatinib) or irreversible pan-HER TKIs (afatinib, dacomitinib and neratinib) have only limited activity against HER2-mutant refractory NSCLC, with response rates ranging between 0% and 19%67–69.